CTLA4 and neoplasm: We first compared side by side the vascular-modulating properties of anti-CTLA-4 mAbs 9D9 and 9H10, using a methylcholanthrene (MCA)-induced mouse tumor model (MCAprog) in which TA-HEVs spontaneously develop and mediate lymphocyte infiltration into tumors.11